Julie Westerlin Kjeldsen

Medicine & Life Sciences

1. Melanoma 100%
2. Tumor-Infiltrating Lymphocytes 99%
3. T-Lymphocytes 85%
4. Neoplasms 66%
5. Indoleamine-Pyrrole 2,3,-Dioxygenase 64%
6. Cell- and Tissue-Based Therapy 64%
7. Vaccines 60%
8. Subunit Vaccines 59%
9. Nivolumab 50%
10. Peptides 37%
11. T-Lymphocyte Subsets 35%
12. Vaccination 35%
13. Ovarian Neoplasms 29%
14. Calreticulin 22%
15. Arginase 20%
16. Follicular Lymphoma 19%
17. Therapeutics 15%
18. Ligands 15%
19. Cellular Immunity 15%
20. Renal Cell Carcinoma 15%
21. Immunotherapy 15%
22. Antigens 14%
23. Histocompatibility Antigens Class II 14%
24. Non-Small Cell Lung Carcinoma 14%
25. Exons 13%
26. Prostatic Neoplasms 12%
27. Organized Financing 12%
28. Phenotype 12%
29. Safety 11%
30. Vemurafenib 11%
31. Clinical Trials, Phase I 10%
32. Blood Cells 9%
33. Mutation 8%
34. Tumor Microenvironment 8%
35. B-Cell Lymphoma 8%
36. In Vitro Techniques 8%
37. Ipilimumab 7%
38. Adoptive Transfer 7%
39. Phase II Clinical Trials 5%
40. Progression-Free Survival 5%
41. Confidence Intervals 5%
42. Cytokines 5%
43. Denmark 5%
44. pembrolizumab 5%
45. Drug Therapy 5%
46. Interleukin-2 5%
47. Immune System 5%